Publication:
Pazopanib for metastatic soft-tissue sarcoma: A multicenter retrospective study

Simple item page
dc.contributor.authorDANE, FAYSAL
dc.contributor.authorsKoca, Sinan; Besiroglu, Mehmet; Ozcelik, Melike; Karaca, Mustafa; Bilici, Mehmet; Hacioglu, Bekir; Dogu, Gamze G.; Kaplan, Nihal B.; Oruc, Zeynep; Aydin, Dincer; Dane, Faysal
dc.date.accessioned2022-03-12T22:54:56Z
dc.date.available2022-03-12T22:54:56Z
dc.date.issued2021
dc.description.abstractPurpose Soft tissue sarcomas are associated with a poor prognosis and low chemotherapeutic efficiency. Pazopanib is an orally available multi-tyrosine kinase inhibitor that was explored in patients with non-adipocytic advanced soft tissue sarcomas. The aim of this retrospective study was to evaluate the real life data of single-agent pazopanib efficacy and safety for soft tissue sarcomas in the Turkish population. Materials and methods We evaluated a total of 103 patients (41 males, 62 females) who received pazopanib for advanced non-adipocytic soft tissue sarcomas diagnosis in eight centers of Turkey, retrospectively. The pazopanib dose was 800 mg once daily. Progression-free survival, overall survival, and adverse events were analyzed. Results The median age was 50 years (range, 38-58). Majority of the patients had leimyosarcoma (41%). Median progression-free survival was 4.3 months, and the median overall survival was 10.1 months. The main common toxicities were fatigue, anorexia, weight loss, nausea, hypertension, and grade >= 3 toxicities were fatigue, anorexia, weight loss, and liver disorder. Conclusion Pazopanib is an efficient and tolerable agent and is well tolerated in good performance status patients with relapsed, advanced non-adipocytic soft tissue sarcomas.
dc.identifier.doi10.1177/1078155220924075
dc.identifier.eissn1477-092X
dc.identifier.issn1078-1552
dc.identifier.pubmed32419618
dc.identifier.urihttps://hdl.handle.net/11424/236584
dc.identifier.wosWOS:000534051900001
dc.language.isoeng
dc.publisherSAGE PUBLICATIONS LTD
dc.relation.ispartofJOURNAL OF ONCOLOGY PHARMACY PRACTICE
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.subjectPazopanib
dc.subjectsoft tissue sarcoma
dc.subjecttargeted therapy
dc.subjectRANDOMIZED PHASE-II
dc.subjectSPANISH GROUP
dc.subjectGEMCITABINE
dc.subjectRISK
dc.titlePazopanib for metastatic soft-tissue sarcoma: A multicenter retrospective study
dc.typearticle
dspace.entity.typePublication
local.avesis.id71b5c856-c854-4622-9f58-caf27833129e
local.import.packageSS17
local.indexed.atWOS
local.indexed.atSCOPUS
local.indexed.atPUBMED
local.journal.articlenumber1078155220924070
local.journal.numberofpages6
local.journal.quartileQ4
oaire.citation.endPage546
oaire.citation.issue3
oaire.citation.startPage541
oaire.citation.titleJOURNAL OF ONCOLOGY PHARMACY PRACTICE
oaire.citation.volume27
relation.isAuthorOfPublication059ce50a-8d16-4fc6-a86c-85c9baa19a5c
relation.isAuthorOfPublication.latestForDiscovery059ce50a-8d16-4fc6-a86c-85c9baa19a5c

Files

Collections

Research Outputs